Table 1:

Description of the three chordoma patient cohorts included in this study

	RNAseq cohort (N= 48)	Nanostring cohort (N= 48)	Survival analysis cohort (N= 312)
Variables	N (%) Mean (SD)	N (%) Mean (SD)	N (%) Mean (SD)	P-valuea
Age (year)	43.6 (18.7)	50.0 (16.4)	40.7 (14.5)	0.0004
<25	10 (20.8)	5 (10.4)	51 (16.3)	<.0001
25–50	15 (31.3)	13 (27.1)	172 (55.1)
≥50	23 (49.9)	30 (62.5)	89 (28.6)
Missing
Sex
F	17 (35.4)	23 (47.9)	137 (43.9)	0.4323
M	31 (64.6)	25 (52.1)	175 (56.1)
Missing
Tumor site
Skull/face	48 (100)	23 (48.9)	312 (100)	<.0001
Pelvic/sacrum	0 (0)	12 (25.5)	0 (0)
Vertebral	0 (0)	12 (25.6)	0 (0)
Missing		1
Histological type
Classic	26 (54.2)	47 (97.9)	227 (72.7)	<.0001
Chondroid	22 (45.8)	1 (2.1)	82 (26.3)
Poorly differentiated	0 (0)	0 (0)	3 (1.0)
Dedifferentiated	0 (0)	0 (0)	0 (0)
Missing
Pre-surgery RTb treatment
No	46 (95.8)		266 (85.3)	0.0419
Yes	2 (4.2)		46 (14.7)
Missing
Post-surgery RTb treatment
No	27 (56.3)		151 (58.5)	0.8736
Yes	21 (43.7)		107 (41.5)
Missing			54
Post-surgery RTb treatment type
Proton	11 (45.8)		16 (20.0)	<.0001
Radiosurgery	2 (8.4)		47 (58.8)
Photon/Carbon	11 (45.8)		0 (0)
Intensity-modulated radiation therapy	0 (0)		17 (21.2)
Missing			27
Recurrence status
No	18 (37.5)		83 (28.9)	0.1944
Yes	30 (62.5)		204 (71.1)
Missing			25
Recurrence-free survival (month)	22 (2–53)		33 (0–141)	0.0378
Death status
No	39 (81.2)		158 (50.7)	<.0001
Yes	9 (18.8)		154 (49.3)
Missing
Overall survival (month)	52 (10–174)		61 (0–140)	0.0916

^aResults from Chi-square, Fisher’s Exact, or ANOVA tests.

^bRadiation therapy